Feature | Stents | May 16, 2016

Cordis Returns to Drug-eluting Stent Market

Cardinal Health signs distribution agreement with Biosensors to expand Cordis’ cardiovascular product offering 

Biosensors' Biomatrix stent.

May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables Cordis, Cardinal Health’s interventional vascular business, to sell Biosensors’ coronary stent portfolio. Cordis will sell Biosensors’ coronary stents in select countries in Europe, the Middle East, Africa, Australia and New Zealand. This marks Cordis’ return to the drug-eluting stent (DES) market and the beginning of a long-term partnership between Cardinal Health and Biosensors to further leverage their respective distribution capabilities in select regions. 

Cordis will now offer an expanded portfolio of products in select countries to further support the treatment of patients undergoing percutaneous coronary intervention (PCI), from access to intervention and closure. PCI is a nonsurgical procedure that often uses a catheter to place a stent to open blocked coronary arteries caused by coronary artery disease. Coronary artery disease is the most common type of heart disease and is expected to continue to be the leading cause of death globally for the next 20 years. 

“We are very excited about this DES agreement with Biosensors, because it represents our strong commitment to expand our product portfolio to support the demands in cardiovascular care today,” said David Wilson, president of Cordis, a Cardinal Health company. “While Cordis is known for developing product innovations, partnerships like this provide an opportunity to rapidly expand our unmatched portfolio and deliver increased value to customers and the patients they serve.” 

In the next few months, Cordis will begin offering Biosensors’ coronary stent portfolio, which includes the BioFreedom polymer-free drug-coated stent; the BioMatrix NeoFlex DES; BioMatrix Alpha, a cobalt chromium DES with an abluminal bio-absorbable coating; and the Chroma cobalt chromium bare metal stent (BMS), in select European countries, Australia and New Zealand. Over time, Cordis will begin to sell these products under the Lumeno private label in select countries, and both companies will continue to leverage their respective distribution capabilities in additional European countries, the Middle East, Africa and other parts of the world. 

Biosensors’ DES with a bio-absorbable coating and the Biolimus A9 drug are supported by multiple large-scale studies, including data from LEADERS, a prospective, randomized, multi-center clinical trial that demonstrated that the safety and efficacy of Biosensors’ BioMatrix Flex stent is comparable to that of a durable polymer DES in a population of 1,707 patients across 10 European centers. Additionally, data published in the New England Journal of Medicine from LEADERS FREE — the first prospective, double-blind, randomized clinical trial exclusively focusing on patients at high-bleeding risk receiving only one month of dual anti-platelet therapy (DAPT) — demonstrated superiority with respect to the primary safety and efficacy endpoints for BioFreedom as compared to a BMS in patients undergoing PCI. The trial assessed the shortest course of DAPT ever used with an active stent. LEADERS FREE included 2,466 patients across 68 sites in 20 countries in Europe, Asia, Australia and Canada, with a follow-up phase of two years.

Biosensors’ coronary stents have not been approved by the U.S. Food and Drug Administration and are not commercially available in the United States.

For more information: www.cordis.com



Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init